{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Later this month, the Synergen Corporation will complete clinical trials of a new biotechnology drug for treating sepsis, a deadly bacterial infection. With the spotlight on health-care costs, Synergen intends to show that its new molecule not only saves lives but also saves money over other sepsis treatments. Drugs have long been held to just two standards -- safety and efficacy. But huge customers like insurance companies and health maintenance organizations are beginning to insist on a third: cost-effectiveness -- that is, whether one drug more than another can reduce hospital stays, say, or employee absenteeism. Standard Gains Support The criterion is gaining sway with Government regulators and may be embraced by the Clinton Administration, which has vowed to make drug-price containment a cornerstone of its plan to cut the nation's health-care bill.", "headline": {"main": "New Standard for Drug Makers: Proving the Cure Is Worth the Cost"}, "abstract": null, "print_page": "1", "word_count": 1415, "_id": "4fd1db858eb7c8105d71c380", "snippet": "Later this month, the Synergen Corporation will complete clinical trials of a new biotechnology drug for treating sepsis, a deadly bacterial infection. With the spotlight on health-care costs, Synergen intends to show that its new molecule not only...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1993/01/18/us/new-standard-for-drug-makers-proving-the-cure-is-worth-the-cost.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "CLINTON, BILL"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "SYNERGEN CORP"}, {"name": "subject", "value": "HEALTH INSURANCE"}, {"name": "subject", "value": "UNITED STATES ECONOMY"}, {"name": "subject", "value": "PRICES"}, {"name": "subject", "value": "ELECTION ISSUES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "NEW MODELS, DESIGN AND PRODUCTS"}, {"name": "subject", "value": "PRESIDENTIAL ELECTION OF 1992"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1}], "original": "By LAWRENCE M. FISHER"}, "document_type": "article", "pub_date": "1993-01-18T00:00:00Z", "section_name": "Front Page; Health; U.S."}], "meta": {"hits": 1, "offset": 0, "time": 29}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}